Biotech Deals Madrigal Secures $2B Deal for CSPC’s Preclinical GLP-1 Madrigal Pharmaceuticals has partnered with China’s CSPC in a $2B deal for SYH2086, an oral GLP-1 candidate for MASH and metabolic disease.